trending Market Intelligence /marketintelligence/en/news-insights/trending/vyrahsww1fnocvnbi3safg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Johnson & Johnson to expand coverage of joints drug

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Johnson & Johnson to expand coverage of joints drug

Janssen Biotech Inc. sought U.S. FDA approval to expand Simponi Aria's coverage as a treatment for active psoriatic arthritis and active ankylosing spondylitis.

The Johnson & Johnson unit filed two supplemental biologics license applications for the drug, which is already approved as a therapy for adult patients with moderate to severe active rheumatoid arthritis.

Psoriatic arthritis and ankylosing spondylitis affect more than 2 million Americans, Johnson & Johnson noted in a news release.

Arthritis is any disorder that affects joints. Ankylosing spondylitis is a form of arthritis.